BioOra milestone for Christchurch immunotherapy facility

BioOra has marked a major milestone with the site blessing of its new Christchurch immunotherapy facility, strengthening the city’s role in cancer research.

Site blessing of new Christchurch immunotherapy facility

New Zealand biotechnology company BioOra has marked a major milestone with a site blessing for its new immunotherapy manufacturing facility in Christchurch’s Te Papa Hauora Health Precinct, reinforcing the city’s growing role as a centre for world‑class cancer research and treatment.

The ceremony brought together clinicians from across New Zealand, international experts, investors, industry collaborators and civic leaders, highlighting the significance of the development for both patient care and the national economy.

Why Christchurch is emerging as a leader in advanced cancer care?

Speaking at the event, Ian Town, Chief Science Advisor to the Ministry of Health, said Christchurch was emerging as a leader in advanced cancer therapies.

“Christchurch is positioning itself as a leading centre for cancer research and treatment,” Town said. “Having international experts here today reinforces that reputation. These innovative therapies are the future of cancer care in New Zealand.”

What the BioOra facility will deliver for patients and the economy

BioOra’s Christchurch facility will support the delivery of next‑generation CAR‑T cell immunotherapy, a highly personalised cancer treatment that uses a patient’s own immune cells. Economic analysis indicates the facility has the potential to generate around $98 million in annual GDP for New Zealand, based on treating approximately 500 patients per year, with a further $16.6 million GDP contribution during construction.

Once operational, the facility is projected to support approximately 1,100 full‑time equivalent jobs annually across healthcare, manufacturing, tourism and supporting services, including more than 480 direct, high‑value roles.

Ali Adams, Chief Executive of ChristchurchNZ, said BioOra’s decision to locate in Christchurch reflected confidence in the city’s innovation ecosystem.

“This facility represents confidence in Christchurch’s ability to support science that genuinely changes lives. It shows that Christchurch is not only a place where great ideas begin, but where world‑class health innovation can scale and succeed.”

Ali Adams - Chief Executive, ChristchurchNZ

Delivering world‑class expertise with measurable patient impact

International learnings shared at the ceremony underscored the patient impact of the technology. Attendees heard from Dr Stella Davies, a global leader in paediatric CAR‑T therapy from Cincinnati Children’s Hospital Medical Center, about the transformational potential of the treatment.

“These therapies are genuinely revolutionary,” Davies said. “CAR‑T can work much more rapidly, with early remission occurring in as little as 28 days — a dramatically improved experience for patients and their families.”

David Downs, Chief Executive of New Zealand Story Group and Education New Zealand, described the significance of the day as both professional and deeply personal.

“This is an emotional day,” Downs said. “I was one of the people who had to go overseas for CAR‑T therapy eight years ago. To see a permanent facility becoming a reality in New Zealand — and with future potential for paediatric patients — is incredibly special.”

How Christchurch is rising as a global hub for health innovation

Downs said the development would firmly place Christchurch on the global innovation map.

“This is world‑leading work. We’re partnering with places like Cincinnati Children’s Hospital, developing clinical trials, and implementing therapies that aren’t widely available globally. To have that happening here puts Christchurch firmly on the international stage.”

Why BioOra chose Christchurch

BioOra Chief Executive John Robson said Christchurch stood out early in the site selection process.

“It was close to love at first sight,” Robson said. “ChristchurchNZ understood what we were trying to achieve and helped connect us to the right people, talent and infrastructure. When we found this site, everything we needed was here — the hospital, the health precinct, the ecosystem.”

"ChristchurchNZ understood what we were trying to achieve and helped connect us to the right people, talent and infrastructure."

John Robson - Chief Executive, BioOra

Why is this a milestone moment for Christchurch and New Zealand?

Robson said the goal was to bring potentially curative treatments to New Zealand patients who currently have limited or no other options.

“What we’re developing has real curative potential, particularly for cancers like lymphoma,” he said. “This is about bringing a level of treatment to New Zealand that has, until now, largely only been available overseas.”

Adams said today’s blessing marked more than the start of a new facility.

“This is about intention — recognising the people, the kaupapa and the purpose behind this place,” she said. “What is being created here will have an impact far beyond these walls, and Christchurch is proud to be part of that journey.”

The facility is expected to open on 7 October 2026.

Key takeaways

New immunotherapy facility blessed: BioOra marked a major milestone with the blessing of its new CAR‑T immunotherapy manufacturing facility in Christchurch’s Te Papa Hauora Health Precinct.
Improved access to cancer treatment: The facility will enable New Zealand patients to access next‑generation, personalised CAR‑T therapies domestically, reducing the need for overseas care.
Strong economic impact: Economic analysis indicates the facility could generate around $98 million in annual GDP, with a further $16.6 million GDP contribution during construction.
Jobs and global positioning: Once operational, the facility is expected to support approximately 1,100 jobs annually and further position Christchurch as a global centre for health innovation.